To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
-
Publication number: 20130059851Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.Type: ApplicationFiled: March 9, 2011Publication date: March 7, 2013Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Levi A. Garraway, Cory M. Johannessen
-
Publication number: 20130058923Abstract: Included in the disclosure is description of a method of determining a presence, and/or aggressiveness level, and/or response to therapy of a human disease in a subject.Type: ApplicationFiled: August 3, 2012Publication date: March 7, 2013Inventor: Qun Huo
-
Patent number: 8389227Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: June 5, 2009Date of Patent: March 5, 2013Assignees: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recera I Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres
-
Publication number: 20130053384Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described.Type: ApplicationFiled: August 24, 2012Publication date: February 28, 2013Applicant: NeuPharma, Inc.Inventors: Yong-Liang Zhu, Xiangping Qian
-
Publication number: 20130052640Abstract: Clostridium difficile disease involves a range of clinical presentations ranging from carrier status with other causes of symptoms to mild and self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on the presence and then the severity of disease. Patients that are carriers may not receive treatment with concern of causing the disease. Mild to moderate cases may be treated with metronidazole while severe and relapsing cases are often treated with vancomycin or fidaxomicin. Current molecular assays are highly sensitive for detecting toxigenic C. difficile and cannot rule out carrier status. Utilization of a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin allows clinicians to differentiate between a carrier state and active state of C. difficile and allows for monitoring to evaluate the effectiveness of treatment.Type: ApplicationFiled: October 30, 2012Publication date: February 28, 2013Applicant: TECHLAB, INC.Inventor: TECHLAB, INC.
-
Publication number: 20130053262Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.Type: ApplicationFiled: December 2, 2010Publication date: February 28, 2013Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventor: Wanlong Ma
-
Publication number: 20130052658Abstract: An object of the present invention is to provide a method of reducing interference to a measurement system from water-soluble silicone and/or surfactant contaminating the measurement system in a latex agglutination immunoassay. The execution of a latex immunoagglutination reaction in the presence of a silicone compound can reduce the interference to the measurement system from a component derived from a micro blood-collection tube (water-soluble silicone) and/or surfactant mixed from outside of the measurement system.Type: ApplicationFiled: March 31, 2011Publication date: February 28, 2013Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Hiroshi Takahashi, Yuki Takahashi, Kazunori Saito
-
Publication number: 20130052659Abstract: A method for measuring immunoglobulin G-mediated complement activation, includes the following steps: a) preparing a sample A of immunoglobulin G and a sample B including natural serum, the natural serum optionally being diluted in a dilution buffer; b) mixing sample A with sample B at a ratio (amount of IgG in A in grams):(volume of natural serum in B in liters) of between and 75, at a temperature of between 2° C. and 6° C., and subsequently incubating the resulting reaction mixture at a temperature of between 35° C. and 40° C. for a period of between 30 minutes and 2 hours; c) cooling the reaction mixture obtained at the end of step b) to a temperature of between 0° C. and 4° C. in the presence of EDTA;and d) measuring the amount of C5a fragment in the cooled reaction mixture obtained in c).Type: ApplicationFiled: May 4, 2011Publication date: February 28, 2013Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Frederic Dhainaut, Gerald Perret
-
Publication number: 20130052632Abstract: This invention relates to a method for detecting an analyte in a sample. The method comprises the steps of exposing the sample to a transducer having a pyroelectric or piezoelectric element and electrodes which is capable of transducing a change in energy to an electrical signal, the transducer having at least one reagent proximal thereto, the reagent having a binding site which is capable of binding the analyte or a complex or derivative of the analyte, wherein at least one of the analyte or the complex or derivative of the analyte has a label attached thereto which is capable of absorbing the electromagnetic radiation generated by the radiation source to generate energy by non-radiative decay; irradiating the reagent with a series of pulses of electromagnetic radiation, transducing the energy generated into an electrical signal, detecting the electrical signal and the time delay between each pulse of electromagnetic radiation from the radiation source and the generation of the electric signal.Type: ApplicationFiled: January 4, 2011Publication date: February 28, 2013Applicant: VIVACTA LIMITEDInventors: Timothy Joseph Nicholas Carter, Steven Andrew Ross
-
Publication number: 20130053271Abstract: A flexible method for making multiplexed assays for antigen-specific antibody responses is disclosed herein. The method of the present invention comprises incubation of a substrate or a set of beads coated with a dockerin or a cohesin protein with a cohesin or dockerin-antigen fusion proteins to attach the fusion protein essentially irreversibly by non-covalent interaction. The present invention enables the use of one dockerin- or cohesin-coated bead for multiple sets of cohesin- or dockerin-antigens, obviating the need to directly chemically couple new antigens to new beads.Type: ApplicationFiled: August 24, 2012Publication date: February 28, 2013Applicant: BAYLOR RESEARCH INSTITUTEInventors: Gerard Zurawski, Sandra Zurawski
-
Patent number: 8383359Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.Type: GrantFiled: September 24, 2010Date of Patent: February 26, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: David M. Frucht, Hui Fang
-
Publication number: 20130045890Abstract: The present invention relates generally to a method for predicting the fertility potential in a male mammal. In particular it relates to a method for predicting the fertility potential in a male mammal by determining the expression of at least one protein of the vitamin D metabolising machinery in a semen sample. The expression level of the at least one protein of the vitamin D metabolising machinery is then indicative of the fertility potential of the subject. An object of the present invention relates to a method, which can predict whether the semen quality is sufficient to achieve pregnancy spontaneously or if the couple should proceed to assisted reproduction or further investigation.Type: ApplicationFiled: May 3, 2011Publication date: February 21, 2013Applicant: Rigshospitalet Copenhagen University HospitalInventors: Martin Blomberg Jensen, John Erik Nielsen, Niels Jorgensen, Kristian Almstrup, Henrik Leffers
-
Publication number: 20130046009Abstract: The disclosure is directed to methods of treating hematologic malignancies. More particularly, the disclosure is directed to methods of treating hematologic malignancies using Rho kinase (ROCK) inhibitors and myosin light chain-specific inhibitory RNA molecules. The disclosure is further directed to methods of identifying drug candidates for inhibiting ROCK in hematologic malignancies.Type: ApplicationFiled: August 15, 2012Publication date: February 21, 2013Inventor: Reuben Kapur
-
Publication number: 20130045887Abstract: A method for identifying persons with increased risk of developing type 1 diabetes mellitus, or having type I diabetes mellitus, utilizing selected biomarkers described herein either alone or in combination. The present disclosure allows for broad based, reliable, screening of large population bases. Also provided are arrays and kits that can be used to perform such methods.Type: ApplicationFiled: August 15, 2012Publication date: February 21, 2013Inventors: Qibin Zhang, Thomas O. Metz
-
Publication number: 20130046010Abstract: Disclosed herein are methods relating to inhibiting or reducing proliferation of a cancer cell, for treating cancer in a subject in need of treatment, predicting the risk of progression of cancer to a more aggressive cancer, and screening for cancer in a subject, that comprise detecting and/or decreasing the levels of SUMO conjugated proteins and detecting and/or interfering with SUMO conjugation.Type: ApplicationFiled: April 15, 2011Publication date: February 21, 2013Applicant: DUKE UNIVERSITYInventors: Wulf Paschen, Wei Yang, Huaxin Sheng, David S. Warner
-
Publication number: 20130039854Abstract: A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.Type: ApplicationFiled: July 26, 2012Publication date: February 14, 2013Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Jean C. SHIH, Leland CHUNG, Haiyen E. ZHAU, Boyang Jason WU, Bogdan Z. OLENYUK
-
Publication number: 20130041012Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20130041016Abstract: Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also provided.Type: ApplicationFiled: September 17, 2012Publication date: February 14, 2013Applicant: Trustees of Dartmouth CollegeInventors: Ethan Dmitrovsky, Bret C. Hassel, Sutisak Kitareewan, Ian Pitha-Rowe
-
Publication number: 20130040311Abstract: [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of any of SEQ ID NOs: 1 to 3, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.Type: ApplicationFiled: March 8, 2011Publication date: February 14, 2013Applicant: FUJIFILM CORPORATIONInventors: Sumio Sugano, Yukari Kanzaki, Tsuneo Saga, Atsushi Tsuji
-
Publication number: 20130040839Abstract: The invention relates to the discovery and use of novel antigens/autoantigens, polyclonal and monoclonal antibodies/autoantibodies thereto, and in particular methods of using the antigens/autoantigens and antibodies/autoantibodies in the diagnostic, prognostic, staging and therapeutic regimens for the control of colorectal cancer.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Inventors: Mark J. Lim, Christopher Sears, Kenneth J. Rothschild
-
Publication number: 20130039859Abstract: Passivated semiconductor nanoparticles and methods for the fabrication and use of passivated semiconductor nanoparticles is provided herein.Type: ApplicationFiled: September 23, 2010Publication date: February 14, 2013Inventors: Lianhua Qu, Gregory Miller
-
Publication number: 20130040301Abstract: The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of genes in rejection-associated gene clusters. The disclosed gene clusters include genes that are substantially co-expressed with cytotoxic lymphocyte pro-apoptotic genes, cytoprotective genes and several other cytokine and immune cell genes.Type: ApplicationFiled: February 1, 2012Publication date: February 14, 2013Applicants: CORNELL RESEARCH FOUNDATION, INC., BETH ISRAEL DEACONESS MEDICAL CENTER, INC.Inventors: Terry B. Strom, Lauro Vasconcellos, Manikkam Suthanthiran
-
Publication number: 20130040310Abstract: This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy.Type: ApplicationFiled: December 15, 2010Publication date: February 14, 2013Applicant: Salk Institute for Biological StudiesInventors: Reuben Shaw, Daniel F. Egan, Maria Mihavlova, David Shackelford
-
Publication number: 20130041015Abstract: In one aspect, B1,4GalT-V, an isoform of the enzyme lactosylceramide synthase, is provided as a biomarker for cancer. Also provided are methods and compositions directed at cancers characterized by the overexpression or upregulation of the lactosylceramide synthase isoform B1,4GalT-V.Type: ApplicationFiled: February 12, 2010Publication date: February 14, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: Subroto Chatterjee
-
Publication number: 20130041013Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20130040312Abstract: Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.Type: ApplicationFiled: October 12, 2012Publication date: February 14, 2013Inventors: Jonathan Matthew BARASCH, Prasad DEVARAJAN, Thomas L. NICKOLAS, Kiyoshi MORI
-
Publication number: 20130040309Abstract: The invention includes compositions, methods and kits for the in vivo identification of an enzyme that binds to a substrate. The invention comprises, in part, a photoreactive moiety to aid in identification of such an enzyme.Type: ApplicationFiled: September 22, 2010Publication date: February 14, 2013Inventors: James Eberwine, Ülo Langel, Emelia Eiriksdóttir, Anup Sharma
-
Publication number: 20130034863Abstract: Apparatus and methods for detecting an a biomarker indicative of an inflammatory condition, including a capillary tube adapted for one or more biomarkers to adhere to an interior surface thereof, a light source for energizing quantum dots conjugated with the biomarkers within the capillary tube, and a detection system for detecting and quantifying fluorescent energy emitted by the quantum dots in one or more predetermined wavelength ranges, each wavelength range being correlated to one and only one of the biomarkers. A method of stabilizing the fluorescence intensity of quantum dots is also disclosed.Type: ApplicationFiled: January 22, 2010Publication date: February 7, 2013Inventors: Elisabeth S. Papazoglou, Sreekant Murthy, Sundar Babu Nadarajan, Sakya Sing Mohapatra
-
Publication number: 20130034864Abstract: Methods for determining the occurrence or level of a mammalian protein in a sample and methods for determining the capability of a compound to transform or to inhibit the transformation of a selected mammalian protein in pro-phospholipase B form to an enzyme active phospholipase B form employ a pro-phospholipase B (PLB-II) mammalian protein which comprises at least one SU2 subunit comprising SEQ ID NO: 3 and having a molecular weight within the range of 30-60 kDa. Methods for determining the capability of a compound to enhance or inhibit the enzymatic activity of a selected protein having phospholipase B enzyme activity employ a protein comprising an activated form of such a pro-phospholipase B (PLB-II) mammalian protein.Type: ApplicationFiled: October 15, 2012Publication date: February 7, 2013Applicant: P&M VENGE ABInventor: P&M VENGE AB
-
Publication number: 20130034854Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.Type: ApplicationFiled: April 27, 2011Publication date: February 7, 2013Applicant: VENTANA MEDICAL SYSTEMS, INC.Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
-
Publication number: 20130035253Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations.Type: ApplicationFiled: August 3, 2012Publication date: February 7, 2013Applicant: Nodality, Inc. A Delaware CorporationInventors: David B. Rosen, Santosh K. Putta, Brent Louie, Norman Purvis
-
Patent number: 8367830Abstract: The present invention relates to immobilization compounds of formula (I), immobilization products and preparations thereof as well as methods and uses for the identification of phosphatidylinositol kinase interacting compounds or for the purification or identification of phosphatidylinositol kinase proteins.Type: GrantFiled: May 14, 2010Date of Patent: February 5, 2013Assignee: Cellzome AGInventors: Kathryn Bell, Nigel Ramsden, Giovanna Bergamini Moore, Gitte Neubauer
-
Patent number: 8367356Abstract: The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide (a.k.a., the target polypeptide) in a test sample as well as to purify native gelsolin proteins. Gelsolin binding agents are also useful to diagnose, a gelsolin related medical condition in subjects in need thereof. Kits to detect gelsolin in biological samples are provided by the present invention.Type: GrantFiled: August 15, 2007Date of Patent: February 5, 2013Assignee: Beijing Cotimes Biotech Co., Ltd.Inventors: Enyun Shen, Zheng Yu, Min Zhou, Fei Guo
-
Publication number: 20130029351Abstract: The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria.Type: ApplicationFiled: January 25, 2011Publication date: January 31, 2013Inventors: Brion Mermer, William J. Palin, Nancy Turcotte
-
Publication number: 20130029868Abstract: This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention.Type: ApplicationFiled: July 25, 2012Publication date: January 31, 2013Inventor: José Alberto ORFAO DE MATOS CORREIA E VALE
-
Publication number: 20130028856Abstract: Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.Type: ApplicationFiled: February 22, 2012Publication date: January 31, 2013Inventors: Gregory I. Frost, Ping Jiang, Curtis B. Thompson
-
Publication number: 20130029352Abstract: Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.Type: ApplicationFiled: September 26, 2012Publication date: January 31, 2013Inventors: Donald P. Bottaro, Gagani P. Athauda, Teresa Lynn Burgess
-
Publication number: 20130029318Abstract: Systems and methods for medical diagnosis or risk assessment for a patient are provided. A fluid-testing microchip is described which includes a filter compartment configured to receive a fluid sample from an inlet port, wherein the filter compartment comprises a plurality of beads coated with a defoaming agent, a micro-pump configured to transfer the fluid sample from the filter compartment to a test compartment, and the test compartment comprising a test component configured to test the fluid sample. The systems include an instrument for reading or evaluating the test data. These systems and methods are designed to be employed at the point of care, such as in emergency rooms and operating rooms, or in any situation in which a rapid and accurate result is desired.Type: ApplicationFiled: July 25, 2011Publication date: January 31, 2013Applicant: EMPIRE TECHNOLOGY DEVELOPMENT LLCInventor: Yasuhisa Fujii
-
Publication number: 20130029859Abstract: A process and assay for determining the neurological condition in a subject is provided whereby the level of one or more neuroactive biomarkers is measured in a sample obtained from the subject. The processes and assay include measurement of multiple neuroactive biomarkers for synergistic determination of a neurological condition such as neurological damage due to injury, disease, contact with a compound, or other source.Type: ApplicationFiled: June 21, 2010Publication date: January 31, 2013Inventors: Stanislav I. Svetlov, Juan Martinez, Stephen Frank Larner, Kevin Ka-wang Wang
-
Publication number: 20130029353Abstract: The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyteType: ApplicationFiled: October 2, 2012Publication date: January 31, 2013Applicant: Abbott LaboratoriesInventor: Abbott Laboratories
-
Publication number: 20130028899Abstract: Inhibitors of Late SV-40 Factor (LSF) are used to treat cancers such as hepatocellular carcinoma (HCC). In particular, small molecule chemical LSF inhibitors are employed. In addition, the activity and/or pattern of expression of LSF may is used to diagnose cancer, to characterize the cancer (e.g. stage, grade, prognosis, etc.) and also to develop suitable protocols for cancer treatment.Type: ApplicationFiled: March 29, 2011Publication date: January 31, 2013Inventors: Devanand Sarkar, Paul B. Fisher
-
Patent number: 8361932Abstract: This invention pertains to the in vitro detection of proteases using a single peptide-conjugate nanocrescent surface enhanced Raman scattering (SERS) probes with at least nanomolar sensitivity. The probe enables detection of proteolytic activity in extremely small volume and at low concentration. In certain embodiments the probes comprise an indicator for the detection of an active protease, where the indicator comprises a nanocrescent attached to a peptide, where said peptide comprises a recognition site for the protease and a Raman tag attached to the peptide.Type: GrantFiled: May 2, 2007Date of Patent: January 29, 2013Assignee: The Regents of the University of CaliforniaInventors: Gang L. Liu, Jonathan A. Ellman, Luke P. Lee, Fanqing Frank Chen
-
Publication number: 20130022617Abstract: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.Inventor: Gera NEUFELD
-
Publication number: 20130022993Abstract: A new compound inhibiting phosphorylation of Ser727 of STAT3, a phosphorylation inhibitor containing the new compound, an insulin resistance improving agent and a preventive or therapeutic agent for diabetes; and a screening method for at least one of the insulin resistance improving agent and the preventive or therapeutic agent for diabetes.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicant: FUJITSU LIMITEDInventors: Kentarou Doi, Takayoshi Kinoshita, Atsushi Tomonaga, Hajime Sugiyama, Mutsuyo Wada
-
Publication number: 20130022983Abstract: Newly identified proteins as markers for the detection of colon and rectal tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, as well as methods for tumor diagnosis and therapy using such ligands.Type: ApplicationFiled: October 26, 2010Publication date: January 24, 2013Applicant: EXTERNAUTICS S.P.A.Inventors: Renata Grifantini, Piero Pileri, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Andrea Pierleoni, Renzo Nogarotto
-
Publication number: 20130022593Abstract: The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis.Type: ApplicationFiled: July 20, 2012Publication date: January 24, 2013Applicant: The Regents of the University of CaliforniaInventor: Linda C. Giudice
-
Publication number: 20130023499Abstract: Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer (e.g., B-cell lymphoma and leukemia), autoimmune diseases, inflammatory diseases, acute inflammatory reactions, and allergic disorders. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for determining the presence or absence of Syk kinase in a sample.Type: ApplicationFiled: January 4, 2012Publication date: January 24, 2013Applicant: Gilead Connecticut, Inc.Inventors: Scott A. MITCHELL, Kevin S. CURRIE, Peter A. BLOMGREN, David M. ARMISTEAD, Joseph RAKER
-
Publication number: 20130022992Abstract: Novel methods for determining the unknown biological activity of a clostridial neurotoxin in a sample with respect to the known biological activity of a clostridial neurotoxin in a reference sample, comprising the step of comparing the biological activity of a clostridial neurotoxin preparation with the biological activity of a standard preparation of a reference clostridial neurotoxin in certain in vitro systems.Type: ApplicationFiled: January 19, 2011Publication date: January 24, 2013Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Thomas Wilk, Harold Victor Taylor, Karl-Heinz Eisele
-
Publication number: 20130023474Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.Type: ApplicationFiled: June 29, 2012Publication date: January 24, 2013Applicant: NGM Biopharmaceuticals, Inc.Inventors: LEI LING, DARRIN A. LINDHOUT
-
Publication number: 20130022583Abstract: Methods, compositions and kits for producing functional neurons, astroctyes, oligodendrocytes and progenitor cells thereof are provided. These methods, compositions and kits find use in producing neurons, astrocytes, oligodendrocytes, and progenitor cells thereof for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the CNS. Also provided are methods, compositions and kits for screening candidate agents for activity in converting cells into neuronal cells, astrocytes, oligodendrocytes, and progenitor cells thereof.Type: ApplicationFiled: January 19, 2011Publication date: January 24, 2013Inventors: Marius Wernig, Thomas C. Sudhof, Thomas Vierbuchen, Austin Ostermeier, Zhiping Pang